Australia must make biotechnology a strategic national industry and build on its clinical trial strengths as political pressure on U.S. scientific institutions and China’s rise reshape global drug ...
Xencor Inc. plans to talk with the U.S. FDA next year about the possibility of accelerated approval for XmAb-819, an ENPP3xCD3 T-cell engaging bispecific antibody, in patients with advanced clear cell ...
The bald figures show U.K. biotech continues to attract funding, but two new reports highlight the ongoing structural weakness of dependence on overseas investors and a lack of the domestic capital ...
Guangzhou Patronus Biotech Co. Ltd. has obtained ethical approval in Australia from Bellberry Ltd. for a first-in-human phase I trial of three novel multi-stage virus-like-particle (VLP)-based ...
Gilead Sciences Inc. is paying $1.28 billion in cash to acquire Pepstar Therapeutics Ltd.’s oral IL-23 receptor inhibitor program, including lead asset HCXT-2001, to deepen its presence in immunology ...
Worldwide biopharma approvals reached 57 in September, up 50% from August’s 38 and coming in as the second-highest monthly total of the year, behind June’s 64.
Cambridge, Mass.-based Alkeus Pharmaceuticals Inc.’s dosing this summer of the first patient in its phase III Northstar study ...
The 2026 European Society of Medical Oncology (ESMO) 2026 annual meeting kicked off with a bit of drama, as Merck & Co. Inc.
A consortium funded by the National Institutes of Health has unveiled the most comprehensive map of somatic mosaicism to date ...
Researchers from Recludix Pharma Inc. presented preclinical data on first-in-class inhibitors of the Bruton tyrosine kinase (BTK) SH2 domain, a novel approach for the treatment of multiple sclerosis ...
Researchers from Oregon Health & Science University investigated the potential of SU-056, a small-molecule Y-box binding protein 1 (YB-1) inhibitor, to directly suppress osteosarcoma and improve ...
Effector memory T cells (TEMs) play a crucial role in the pathogenesis of autoimmune diseases such as inflammatory bowel disease (IBD), and they highly express the voltage-gated potassium channel Kv1.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results